Kooperativer Bibliotheksverbund

Berlin Brandenburg

and
and

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Medium
Language
Year
  • 1
    Language: English
    In: The Lancet, 2006, Vol.368(9552), pp.2039-2041
    Description: Similar data have been recorded in the TREE1 (Three Regimens on Effects of Eloxatin) and TREE2 trials, in which FOLFOX regimens seem to have higher response rates and times to progression than bolus fluorouracil and oxaliplatin regimens.7 Furthermore, the BICC-C (Bolus Infusion Capecitabine Camptosar...
    Keywords: Medicine
    ISSN: 0140-6736
    E-ISSN: 1474-547X
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Cancer, 01 October 2015, Vol.121(19), pp.3481-3490
    Description: CC‐223 inhibits both mTORC1 and mTORC2, a feature thought to increase the efficiency of mTOR pathway suppression that distinguishes this agent from rapamycin and its analogs that primarily target mTORC1 alone. In a phase 1 study of patients with advanced solid tumors or multiple myeloma, CC‐223 was tolerable with manageable toxicities, and treatment was associated with early signs of disease control, including tumor regression.
    Keywords: Akt ; Mtor ; Mtorc1/Mtorc2 ; Rapalogs
    ISSN: 0008-543X
    E-ISSN: 1097-0142
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Language: English
    In: Cancer Research, 07/01/2017, Vol.77(13 Supplement), pp.1778-1778
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Language: English
    In: Cancer Research, 04/15/2011, Vol.71(8 Supplement), pp.1298-1298
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Language: English
    In: Cancer Research, 07/01/2018, Vol.78(13 Supplement), pp.CT126-CT126
    ISSN: 0008-5472
    E-ISSN: 1538-7445
    Source: CrossRef
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    In: Cancer, 01 April 2015, Vol.121(7), pp.1056-1063
    Description: The current phase 1, open‐label, dose escalating, first‐in human study of ME‐344 in patients with refractory solid tumors found that the maximum tolerated dose of once‐weekly 10‐mg/kg administration of the drug was generally well tolerated. The preliminary clinical activity as a monotherapy supports the further clinical development of ME‐344 in combination with chemotherapy.
    Keywords: Me‐344 ; First‐In‐Human ; Mitochondrial Inhibitor ; Phase 1 ; Refractory Solid Tumors ; Maximum Tolerated Dose Mtd
    ISSN: 0008-543X
    E-ISSN: 1097-0142
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    Language: English
    In: Journal of Hematology & Oncology, 01 June 2011, Vol.4(1), p.29
    Description: Abstract Pancreatic neuroendocrine tumors (NET) have diverse clinical presentations. Patients with symptoms of hormone secretion may require specific medical interventions to control those symptoms prior to antitumor intervention. In some patients, tumors in the pancreas may be occult and specialized diagnostic imaging or surgery may be required for diagnosis. Other patients may present with more advanced disease, presenting with symptoms of tumor bulk rather than hormone secretion. Treatment options for patients with advanced pancreatic neuroendocrine tumors include surgical resection and hepatic directed therapies, including partial hepatectomy, hepatic artery embolization, or other ablative techniques. Streptozocin or temozolomide-based chemotherapy regimens are active against pancreatic NET, and can also play an important role in the palliation of patients with advanced disease. A number of biologically targeted agents targeting the VEGF and mTOR signaling pathways have recently shown promise, with recent trials showing treatment with the VEGFR tyrosine kinase inhibitor sunitinib or the mTOR inhibitor everolimus improves progression-free survival in patients with advanced NET.
    Keywords: Medicine
    ISSN: 1756-8722
    E-ISSN: 1756-8722
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Language: English
    In: Journal of Hematology & Oncology, June 14, 2011, Vol.4, p.29
    Description: Pancreatic neuroendocrine tumors (NET) have diverse clinical presentations. Patients with symptoms of hormone secretion may require specific medical interventions to control those symptoms prior to antitumor intervention. In some patients, tumors in the pancreas may be occult and specialized diagnostic imaging or surgery may be required for diagnosis. Other patients may present with more advanced disease, presenting with symptoms of tumor bulk rather than hormone secretion. Treatment options for patients with advanced pancreatic neuroendocrine tumors include surgical resection and hepatic directed therapies, including partial hepatectomy, hepatic artery embolization, or other ablative techniques. Streptozocin or temozolomide-based chemotherapy regimens are active against pancreatic NET, and can also play an important role in the palliation of patients with advanced disease. A number of biologically targeted agents targeting the VEGF and mTOR signaling pathways have recently shown promise, with recent trials showing treatment with the VEGFR tyrosine kinase inhibitor sunitinib or the mTOR inhibitor everolimus improves progression-free survival in patients with advanced NET.
    Keywords: Neuroendocrine Tumors -- Diagnosis ; Neuroendocrine Tumors -- Development And Progression ; Neuroendocrine Tumors -- Care And Treatment ; Neuroendocrine Tumors -- Prognosis ; Neuroendocrine Tumors -- Research
    ISSN: 1756-8722
    Source: Cengage Learning, Inc.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Language: English
    In: Journal of Hematology & Oncology, June 14, 2011, Vol.4, p.29
    Description: Pancreatic neuroendocrine tumors (NET) have diverse clinical presentations. Patients with symptoms of hormone secretion may require specific medical interventions to control those symptoms prior to antitumor intervention. In some patients, tumors in the pancreas may be occult and specialized diagnostic imaging or surgery may be required for diagnosis. Other patients may present with more advanced disease, presenting with symptoms of tumor bulk rather than hormone secretion. Treatment options for patients with advanced pancreatic neuroendocrine tumors include surgical resection and hepatic directed therapies, including partial hepatectomy, hepatic artery embolization, or other ablative techniques. Streptozocin or temozolomide-based chemotherapy regimens are active against pancreatic NET, and can also play an important role in the palliation of patients with advanced disease. A number of biologically targeted agents targeting the VEGF and mTOR signaling pathways have recently shown promise, with recent trials showing treatment with the VEGFR tyrosine kinase inhibitor sunitinib or the mTOR inhibitor everolimus improves progression-free survival in patients with advanced NET.
    Keywords: Neuroendocrine Tumors -- Diagnosis ; Neuroendocrine Tumors -- Development And Progression ; Neuroendocrine Tumors -- Care And Treatment ; Neuroendocrine Tumors -- Prognosis ; Neuroendocrine Tumors -- Research
    ISSN: 1756-8722
    Source: Cengage Learning, Inc.
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages